Molecular Partners’ (MOLN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Molecular Partners (NASDAQ:MOLN) in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $13.00 target price on the stock.

MOLN has been the subject of a number of other research reports. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, April 10th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Stock Performance

Molecular Partners stock opened at $4.52 on Wednesday. The company has a 50 day moving average price of $4.51 and a 200 day moving average price of $4.28. Molecular Partners has a 52 week low of $3.36 and a 52 week high of $5.36. The firm has a market capitalization of $182.48 million, a price-to-earnings ratio of -2.27 and a beta of 1.11.

Molecular Partners (NASDAQ:MOLN) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). Equities analysts forecast that Molecular Partners will post -1.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.